Paediatric reduced intensity conditioning: Analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP

Bone Marrow Transplantation

Volumn 50, Issue 4, 2015, Pages 592-597

  Lawitschka, A ^a   Faraci, M ^b   Yaniv, I ^c   Veys, P ^d   Bader, P ^e   Wachowiak, J ^f   Socie, G ^g   Aljurf, M D ^h   Arat, M ⁱ   Boelens, J J ^j   Duarte, R ^k   Tichelli, A ^l   Peters, C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b G GASLINI INSTITUTE   (Italy)

^c TEL AVIV UNIVERSITY   (Israel)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e Children's Hospital   (Germany)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^g SAINT LOUIS HOSPITAL   (France)

^h KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

ⁱ ANKARA UNIVERSITY   (Turkey)

^j UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^k HOSPITAL DURAN I REYNALS   (Spain)

^l UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; TREOSULFAN; MYELOABLATIVE AGENT; VIDARABINE;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW DEPRESSION; CHILD; GRAFT VERSUS HOST REACTION; HEMOGLOBINOPATHY; HEMOPHAGOCYTIC SYNDROME; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; INFANT; LYMPHATIC LEUKEMIA; MYELOID LEUKEMIA; PRIORITY JOURNAL; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; WHOLE BODY RADIATION; ALLOGRAFT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FACTUAL DATABASE; FEMALE; HEALTH CARE QUALITY; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; PROCEDURES;

ADOLESCENT; ALLOGRAFTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; FEMALE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MYELOABLATIVE AGONISTS; QUALITY OF HEALTH CARE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 84926420865     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.306     Document Type: Article

References (29)

1. Satwani P, Cooper N, Rao K, Veys P, Amrolia P. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant 2008; 41: 173-182
2. Del Toro G, Satwani P, Harrison L, Cheung YK, Brigid Bradley M, George D, et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004; 33: 613-622
3. Gomez-Almaguer D, Ruiz-Arguelles GJ, Tarin-Arzaga Ldel C, Gonzalez-Llano O, Jaime-Perez JC, Lopez-Martinez B, et al. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol Blood Marrow Transplant 2003; 9: 157-161
4. Duerst R, Jacobsohn D, Tse WT, Kletzel M. Efficacy of reduced intensity conditioning (RIC) with FLU-BU-ATG and allogeneic hematopoietic stem cell transplantation (HSCT) for pediatric ALL. ASH Annual Meeting Abstracts 2004; 104: 2314
5. Roman E, Cooney E, Harrison L, Militano O, Wolownik K, Hawks R, et al. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res 2005; 11: 7164 s-7170 s
6. Claviez A, Klingebiel T, Beyer J, Nurnberger W, Ehninger G, Suttorp M, et al. Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease. Ann Hematol 2004; 83: 237-241
7. Nagler A, Labopin M, Shimoni A, Volin L, Bunjes DW, Huynh A, et al. Comparison of outcomes after allogeneic HSCT for adult patients with AML in remission using in the conditioning regimen either I.V. Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An- ALWP-EBMT Survey. ASH Annual Meeting Abstracts 2009; 114: 195
8. Pulsipher MA, Boucher KM, Wall D, Frangoul H, Duval M, Goyal RK, et al. Reducedintensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 2009; 114: 1429-1436
9. Veys P, Rao K, Amrolia P. Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioning. Bone Marrow Tansplant 2005; 35: S45-S47
10. Yaniv I, Stein J, Party EPW. Reduced-intensity conditioning in children: a reappraisal in 2008. Bone Marrow Transplant 2008; 41: S18-S22
11. Strahm B, Locatelli F, Bader P, Ehlert K, Kremens B, Zintl F, et al. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant 2007; 40: 329-333
12. Champlin R, Khouri I, Komblau S, Molidrem J, Giralt S. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graftvs-malignancy effect. Oncology 1999; 13: 621-628 discussion 631, 635-638, 641
13. Bacigalupo A. Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): report of a workshop of the European group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2000; 25: 803-805
14. Bacigalupo A. Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant 2002; 29: 191-195
15. Bacigalupo A. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant 2004; 33: 691-696
16. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633
17. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reducedintensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367-369
18. Apperley J CE, Gluckman E, Masszi T. Principles of conditioning. The EBMT Handbook Haemopoietic Stem Cell Transplantation, 6th edn. European School of Haematology, 2012
19. Gratwohl A, Baldomero H, Passweg J, Urbano-Ispizua A. European Group for Blood and Marrow Transplantation (EBMT). Accreditation Committee. Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplant 2002; 30: 813-831
20. Stein J, Dini G, Yaniv I. Pediatric Diseases Working Party of the EBMT The hope and the reality of reduced intensity transplants in children with malignant diseases. Bone Marrow Transplant 2005; 35: S39-S43
21. Strullu M, Rialland F, Cahu X, Brissot E, Corradini N, Thomas C, et al. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience. Eur J Haematol 2012; 88: 504-509
22. Luger SM, Ringden O, Zhang MJ, Perez WS, Bishop MR, Bornhauser M, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47: 203-211
23. Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005; 105: 879-885
24. Burroughs LM, Storb R, Leisenring WM, Pulsipher MA, Loken MR, Torgerson TR, et al. Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. Bone Marrow Transplant 2007; 40: 633-642
25. Slatter MA, Rao K, Amrolia P, Flood T, Abinun M, Hambleton S, et al. Treosulfanbased conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 2011; 117: 4367-4375
26. Bartelink IH, van Reij EM, Gerhardt CE, van Maarseveen EM, de Wildt A, Versluys B, et al. Fludarabine and exposure-Targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant 2014; 20: 345-353
27. Andreani M, Testi M, Battarra M, Indigeno P, Guagnano A, Polchi P, et al. Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia. Blood Transfus 2008; 6: 143-149
28. Gungor T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reducedintensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 2014; 383: 436-448
29. Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years?. Hematology Am Soc Hematol Educ Prog 2005; 384-389